SEOUL, April 6 (Reuters) – Celltrion Inc’s U.S. Food and Drug Administration-approved biosimilar version of Johnson & Johnson’s drug Remicade is expected to be priced about 20 to 30 percent lower…
The post S.Korea Celltrion expects 20-30 pct discount for Remicade biosimilar appeared first on NASDAQ.